Scott Gottlieb: “I see it as a strengthening, because we are going from a hard threshold of 30 percent to a risk-based threshold of 50…”

the most important incentive to developing useful information remains the ability for companies to market drugs based on what has been proven scientifically.

That's not true. It's highly effective, and that measles itself isn't a bad illness.

Throughout my career I've worked to advance policies to enable terminally ill patients to obtain earlier access to promising new drugs.

IPAB has no obligation to engage in public notice and comment that is customary to regulatory agencies whose decisions have similarly broad implications.